Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will collect skin measurements using the Nevisense Go device from participants with atopic dermatitis over about 90 days. Participants will perform device measurements at home, keep an electronic diary, and attend up to five in-person visits. The goal is to see if changes in skin barrier function, as measured by electrical impedance spectroscopy, precede visible flares and symptoms, helping estimate flare likelihood without guiding treatment during the study. Data will include device readings, diary entries, and clinician assessments to explore associations with flare onset. The study is designed to be non-interventional, with no changes to participants' clinical care based on study measurements.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants may be eligible if they:

* Are 12 to 89 years old.
* Have been diagnosed with atopic dermatitis (eczema).
* Have had at least one atopic dermatitis flare within the past 2 months.
* Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits.
* If currently using systemic treatment for atopic dermatitis, have been on the same treatment for at least 3 months and do not plan to change treatment during the study.

Exclusion Criteria:

Participants may not be eligible if they:

* Are unwilling or unable to avoid applying creams, lotions, ointments, or soap to measurement areas for 6 hours before measurements.
* Do not have suitable skin areas for study measurements.
* Have another skin condition that may affect study assessments.
* Are pregnant.

Where it's running

• U.S. Dermatology Partners
  Phoenix, Arizona, United States Recruiting
• James Y. Wang MD, Inc
  Los Angeles, California, United States Recruiting
• True Blue Clinical Research
  Tampa, Florida, United States Recruiting
• U.S. Dermatology Partners Rockville
  Rockville, Maryland, United States Recruiting
• Derm Research Institute, PLC
  Caledonia, Michigan, United States Recruiting
• U.S. Dermatology Partners Lee's Summit
  Lee's Summit, Missouri, United States Recruiting

Study contacts

• Study coordinator: Clare Johnson E VP Clinical Research
• Email: cjohnson@castlebiosciences.com
• Phone: 602-499-0301

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• ADBest TREAT Registry for adults with atopic dermatitis

  A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07904546

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

• Tilrekimig for moderate-to-severe eczema in teens and adults

  A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.

  Recruiting at 31 sites Phase 3 Pfizer · Birmingham, Alabama and 49 other locations · NCT07783425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.